Samotolisib: Clinical Trials

2 trials of Samotolisib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Active not recruiting 1, Completed 1

Follow Samotolisib: new trials by email Literature Review of Samotolisib trials Research Report on Samotolisib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)182017-11-282026-04-21
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2Active not recruitingNational Cancer Institute (NCI)13772017-07-312026-07-24

Conditions studied

Central Nervous System Neoplasms (2)  ·  Ependymoma (2)  ·  Glioma (2)  ·  Hepatoblastoma (2)  ·  Histiocytosis, Langerhans-Cell (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Medulloblastoma (2)  ·  Neuroblastoma (2)  ·  Neuroectodermal Tumors, Primitive, Peripheral (2)  ·  Osteosarcoma (2)  ·  Rhabdoid Tumor (2)  ·  Rhabdomyosarcoma (2)  ·  Sarcoma (2)  ·  Sarcoma, Ewing (2)  ·  Wilms Tumor (2)

Sponsors

National Cancer Institute (NCI) (2)

Countries

Puerto Rico (2)  ·  United States (2)  ·  Australia (1)  ·  Canada (1)

Top investigators

Donald W Parsons (1)  ·  Theodore W Laetsch (1)

Results publications

PMID 31401903, PMID 33591402, PMID 35353553, PMID 41166674, PMID 42686334

NIH funding

U10CA180886 (2)